Tivic Health Systems Appoints New Transfer Agent: Odyssey Transfer and Trust Company

Tivic Health Systems has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar. The change involves transferring all registered shares and records from Equiniti Trust Company and appointing Odyssey as the successor warrant agent for Series B Warrants. The company's stock score is Neutral due to declining revenues and negative profitability, but recent strategic initiatives provide optimism for future growth.

Tivic Health Systems, Inc. (Nasdaq: TIVC) has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar. The change involves transferring all registered shares and records from Equiniti Trust Company and appointing Odyssey as the successor warrant agent for Series B Warrants. The company's stock score is Neutral due to declining revenues and negative profitability, but recent strategic initiatives provide optimism for future growth.

The appointment of Odyssey Transfer and Trust Company signifies Tivic's ongoing efforts to streamline its operations and enhance its financial infrastructure. The new transfer agent will handle all administrative functions related to Tivic's shares, including shareholder communications, dividend distributions, and proxy voting. This move is expected to improve the efficiency and accuracy of these processes, potentially leading to cost savings and enhanced shareholder services.

Tivic's strategic initiatives, including its recent acquisition of exclusive worldwide rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ from Statera Biopharma [1], have the potential to drive future growth. Entolimod is a promising immunotherapy drug that has shown significant potential in treating acute radiation syndrome (ARS). The FDA has granted Fast Track and Orphan Drug designation to Entolimod, indicating its potential for rapid regulatory approval.

However, Tivic's stock score remains Neutral due to its current financial performance. The company has been experiencing declining revenues and negative profitability, which are key factors contributing to its stock's current valuation. Despite these challenges, Tivic's strategic initiatives and the potential of its product pipeline, including Entolimod and other indications, offer a glimmer of optimism for future growth.

As Tivic continues to navigate these financial challenges, its appointment of a new transfer agent reflects its commitment to operational excellence and shareholder value. The company's focus on strategic initiatives and its ability to leverage its diverse product pipeline will be crucial in turning around its current financial performance and restoring investor confidence.

References:
[1] https://www.businesswire.com/news/home/20250212860402/en/Tivic-Health-Acquires-Exclusive-Worldwide-Rights-to-Phase-III-TLR5-Agonist-from-Statera-Biopharma